Sihem Cheloufi

US Patent:

8273871, Sep 25, 2012

Filed:

Oct 4, 2011

Appl. No.:

13/252784

Inventors:

Gregory J. Hannon - Huntington NY, US
Sihem Cheloufi - Boston MA, US

Assignee:

Cold Spring Harbir Laboratory - Cold Spring Harbor NY

International Classification:

C12Q 1/68
C12P 19/34
C12N 15/63
C07H 21/02
C07H 21/04

US Classification:

536 245, 435 6, 435 911, 435 9131, 435455, 536 231, 536 243

Abstract:

Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.

US Patent:

20130179999, Jul 11, 2013

Filed:

Apr 22, 2011

Appl. No.:

13/642802

Inventors:

Gregory J. Hannon - Cold Spring Harbor NY, US
Sihem Cheloufi - Boston MA, US

Assignee:

COLD SPRING HARBOR LABORATORY - Cold Spring Harbor NY

International Classification:

C12N 15/113

US Classification:

800 14, 536 245, 4353201, 506 16, 435375

Abstract:

Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.

US Patent:

20210254064, Aug 19, 2021

Filed:

Feb 8, 2021

Appl. No.:

17/170047

Inventors:

- Cold Spring Harbor NY, US
Sihem Cheloufi - Boston MA, US

Assignee:

Cold Spring Harbor Laboratory - Cold Spring Harbor NY

International Classification:

C12N 15/113
C12N 15/11

Abstract:

Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.

US Patent:

20200048633, Feb 13, 2020

Filed:

May 6, 2019

Appl. No.:

16/404271

Inventors:

- Cold Spring Harbor NY, US
Sihem Cheloufi - Boston MA, US

Assignee:

Cold Spring Harbor Laboratory - Cold Spring Harbor NY

International Classification:

C12N 15/113
C12N 15/11

Abstract:

Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.

US Patent:

20180327745, Nov 15, 2018

Filed:

Jul 24, 2018

Appl. No.:

16/043639

Inventors:

- Boston MA, US
Sihem CHELOUFI - Boston MA, US

Assignee:

THE GENERAL HOSPITAL CORPORATION - Boston MA

International Classification:

C12N 15/113
C12N 5/074

Abstract:

Provided herein are methods for performing cellular reprogramming that include treatment of somatic cells with an inhibitor of CAF-1, Sumo2, Nutd21, or combinations thereof prior to or during a reprogramming procedure. Such inhibitors can improve both the speed and efficiency of cellular reprogramming. Inhibitors of the CAF-1 complex can also be used in the treatment of cancer.

US Patent:

20170342410, Nov 30, 2017

Filed:

Mar 6, 2017

Appl. No.:

15/451016

Inventors:

Gregory J. Hannon - Cold Spring Harbor NY, US
Sihem Cheloufi - Boston MA, US

Assignee:

Cold Spring Harbor Laboratory - Cold Spring Harbor NY

International Classification:

C12N 15/113
C12N 15/11

Abstract:

Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Agog because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.

US Patent:

20170175120, Jun 22, 2017

Filed:

Feb 27, 2017

Appl. No.:

15/443632

Inventors:

- BOSTON MA, US
Sihem CHELOUFI - Boston MA, US
Marti Anne BORKENT - Boston MA, US

Assignee:

THE GENERAL HOSPITAL CORPORATION - BOSTEN MA

International Classification:

C12N 15/113
C12N 5/074

Abstract:

Provided herein are methods for performing cellular reprogramming that include treatment of somatic cells with an inhibitor of CAF-1, Sumo2, Nutd21, or combinations thereof prior to or during a reprogramming procedure. Such inhibitors can improve both the speed and efficiency of cellular reprogramming. Inhibitors of the CAF-1 complex can also be used in the treatment of cancer.

US Patent:

20150197749, Jul 16, 2015

Filed:

Feb 24, 2015

Appl. No.:

14/630419

Inventors:

Gregory J. Hannon - Cold Spring Harbor NY, US
Sihem Cheloufi - Boston MA, US

Assignee:

Cold Spring Harbor Laboratory - Cold Spring Harbor NY

International Classification:

C12N 15/113

Abstract:

Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.